{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"A maximum of 12 patients will be accrued and DLTs will be assessed in these patients. If any DLT is observed in more than one of the six patient cohort, a lower dose of ipilimumab will be evaluated in a new six patient cohort.","groups":[{"description":"The patient will be admitted to a single room on the Adult Transplantation Service and allogeneic CD34-selected PBSC or marrow transplantation performed as per MSKCC adult BMT guidelines. Patients will be evaluated at approximately day 100 (±2 weeks) after allo-HSCT.\n\nIpilimumab: Ipilimumab 3 mg/kg every 3 weeks for 4 doses.","id":"OG000","title":"Ipilimumab After Stem Cell Transplantation"}],"populationDescription":"Data were not collected","reportingStatus":"POSTED","timeFrame":"1 year","title":"Phase I: Maximum Tolerated Dose of Ipilimumab","type":"PRIMARY"}